Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPAS study of adjuvant tislelizumab plus probiotics after radical surgery for hepatocellular carcinoma with microvascular invasion
ChiCTR2500096804Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and AGU in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Recurrence-free survival. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
tislelizumabAGU
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500096804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096804.